Answers are grounded in this paper and cite their sources.
Background Apremilast is approved for psoriasis and psoriatic arthritis (PsA). Although clinical trials demonstrated efficacy and tolerability of apremilast, real-world data for PsA are lacking. Objective Assess the real-world effectiveness and tolerability of apremilast in German clinical practice. Methods The multicenter, prospective, non-interventional LAPIS-PsA study (conducted from February 2016 to July 2018) enrolled patients diagnosed with moderate to severe PsA (Physician’s Global Assessment [PhGA] ≥2) and insufficient response or intolerance to ≥1 disease-modifying antirheumatic drug who were initiating apremilast in German clinical practice. Outcomes included, but were not limited to, PhGA improvement ≥1 (scale of 0–4) at ~7 months (primary); PhGA improvement ≥1, Patient Global Assessment (PtGA) improvement ≥1; pain visual analog scale (VAS), pruritus VAS, and the 9-item Psoriatic Arthritis Impact of Disease (PsAID-9) over ~13 months (secondary); and minimal disease activity (MDA) (exploratory) over ~13 months. Results A total of 418 patients were analyzed; mean±SD age: 54.9±11.0 years, 59.2% female, 40.8% male. Most (75.6%) patients achieved a PhGA ≥1-point improvement at ~7 months, with responses maintained at ~13 months (72.5%). Over half (58.7%) achieved a PtGA improvement ≥1-point; over one-third (41.5%) achieved MDA at ~13 months. Mean±SD pain and pruritus VAS decreased from 52.1±23.1 and 36.7±30.7 at baseline to 32.6±23.4 and 19.6±21.9 at ~13 months, respectively. Mean (SD) PsAID-9 total score decreased from 5.3±2.1 at baseline to 3.3±2.0 at ~13 months. Conclusion Patients with PsA treated with apremilast in German clinical practice experienced improvements in patient- and physician-reported measures of disease activity over 13 months of treatment.
No takes yet. Share an insight, caveat, or question.
Behrens et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: